ICARE Social Media Post April 2020

Advances in Treatment for Ovarian Cancer in BRCA1/2 Carriers: Niraparib


On April 29, 2020 the FDA approved the use of niraparib (Zeluja) as first-line maintenance treatment in BRCA1/2 carriers with advanced ovarian cancer!

More details available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer

Permanent link to this article: https://inheritedcancer.net/post42920/